Benzinga's Top Initiations - CrossAmerica Partners (NYSE:CAPL)

Analysts at Morgan Stanley initiated coverage on Sarepta Therapeutics Inc SRPT with an Equal-Weight rating. The price target for Sarepta Therapeutics is set to $53. Sarepta shares closed at $44.54 on Wednesday.
Analysts at Buckingham initiated coverage on Fossil Group Inc FOSL with an Underperform rating. The price target for Fossil is set to $23. Fossil shares closed at $29.11 on Wednesday.
Analysts at Aegis Capital initiated coverage of Progenics Pharmaceuticals, Inc. PGNX with a Buy rating. The price target for Progenics Pharmaceuticals is set to $11. Progenics Pharmaceuticals shares closed at $5.15 on Wednesday.
Needham initiated coverage on AMAG Pharmaceuticals, Inc. AMAG with a Buy rating. The price target for AMAG Pharmaceuticals is set to $40. AMAG Pharmaceuticals shares closed at $25.70 on Wednesday.
Leerink Swann assumed coverage on Nabriva Therapeutics AG - ADR NBRV with an Outperform rating. Nabriva Therapeutics shares closed at $5.91 on Wednesday.
Analysts at Wells Fargo initiated coverage of Glaukos Corp GKOS with an Outperform rating. Glaukos shares closed at $34.52 on Wednesday.
Analysts at RBC Capital initiated coverage on Crossamerica Partners LP CAPL with a Sector Perform rating. The price target for Crossamerica Partners is set to $28. Crossamerica Partners shares closed at $26.67 on Wednesday.
Analysts at H.C. Wainwright initiated coverage on OHR Pharmaceutical Inc OHRP with a Buy rating. The price target for OHR Pharmaceutical is set to $10. OHR Pharmaceutical shares closed at $2.95 on Wednesday.
Analysts at Leerink Swann assumed coverage on Paratek Pharmaceuticals Inc PRTK with an Outperform rating. Paratek Pharmaceuticals shares closed at $11.55 on Wednesday.

Market News and Data brought to you by Benzinga APIs